Marinesalvor would be better advised to at least read Neuren's announcements to the ASX rather than relying on the nonsense reported in the Herald. Contrary to what the Herald would have us believe, glypromate is NOT about to start Phase 3 trials. Neuren still has to complete a phase 2 trial which apparently hasn't even started yet. In reality they're no further forward than they were at the time of the float.
As for NNZ-2566, that's nowhere near ready for any human trials and certainly not a phase 3 trial. If David Clarke really told the Herald that "the latest results were sufficient to start stage III human clinical trials" then he's living in cloud cuckoo land. Perhaps he's been sampling Neuren's drugs himself. After all, psychotropic & hallucinatory side effects are well described for other drugs in this class and were what led to Phase 3 trials of other NMDA antagonists being aborted.
looks as though Labrat was wrong. Phase 3 trials have started for Glypormate and the nn... is all go as well in phase 1 trials. Nice bump in the share price too. Would be great to have a really sucessful Kiwi Biotech. Still Phase 3 and Phase 1 is a long way from commercialisation. Will be interesting to see how it goes. Genesis fell at Phase 3 trials.
I have requested a few and I guess takeup was not so hot so the the latest announcements were to boost participation. Looking for news on the Glypromate trials soon.
Not looking good despite upbeat report. Guess I was wrong about this one. Still BZI is looking good.
Anyone have any news on the slump in shareprice. Is it just because the Phase 3 trials don't seem to be moving ahead at all? I am in for the long run and wont be selling but would be interested in the general drift downwards and if anyone has heard anything?
Reply With Quote
Bookmarks